Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2022 | Story Anthony Mthembu

According to the Gender Equality and Anti-Discrimination Office (GEADO) at the University of the Free State (UFS), an alarming number of transgender and gender-diverse persons at South African institutions of higher learning are consistently met with a great deal of neglect and exclusion. Therefore, it is imperative to constantly shine light on the injustice and violation of their human rights in order to enable spaces that acknowledge their lived realities and uphold their human dignity. 

The importance of the march

As such, the Gender Equality and Anti-Discrimination Office will be hosting a transgender march on the Bloemfontein Campus on 17  May 2022. 

“The aim of this march is to raise awareness about issues of transsexuality and gender-diverse individuals. We hope to accentuate the voices of transgender individuals and gender-diverse persons on our campuses,” expressed Delisile Mngadi, Assistant Officer in the Gender Equality and Anti-Discrimination Office. The march will commence at 09:30 from the Main Gate and will end at the Centenary Complex. In addition, members of the Gender Equality and Anti-Discrimination Office argue that the purpose of the march is to remind members of the UFS community and the society at large that the stories, the voices, and experiences of transgender and gender-diverse individuals do matter.

An invitation to staff and students 

Members of the UFS community, regardless of how they identify, are invited to take part in the march. “It is also important that cishetero persons attend the march; this shows that they stand in support of all gender-diverse persons, and it is also a great opportunity to learn.  Another reason why it is important for cisgender persons to attend the march is because violence and discrimination targeted at transgender persons remain a daily reality on our campuses, which inadvertently maintains heteronormative notions and patriarchal power that validates transphobia and homophobia,” Mngadi indicated. 

UFS staff and students who will be in attendance can expect to hear speeches from a few invited dignitaries. In addition, Mngadi, along with other members of the office, maintains that this is an opportunity for staff and students to engage with one another. The march is particularly important because it will teach staff and students “to be aware of the diversity that exists within our institution, a diversity that transcends language, religion, and ethnicity – to name just a few. People will also learn to respect this diversity, and most importantly, to understand that all lives matter”, said Mngadi.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept